We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Celgene Corporation | NASDAQ:CELG | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 108.24 | 109.30 | 109.44 | 0 | 01:00:00 |
From May 2019 to May 2024
By Colin Kellaher
Mereo BioPharma Group PLC (MREO, MPH.LN) on Thursday said Celgene Corp. (CELG) won't exercise its option to license the cancer treatment etigilimab, one of two product candidates Mereo acquired in its April takeover of OncoMed Pharmaceuticals Inc.
Mereo, a London clinical-stage biopharmaceutical company focused on rare diseases, said Celgene's decision was based on strategic portfolio considerations. The Summit, N.J., biopharmaceutical company is in the process of being acquired by Bristol-Myers Squibb Co. (BMY).
As a result of Celgene's decision, Mereo said holders of the contingent value rights that OncoMed issued related to etigilimab won't receive any payments.
Mereo, which will retain the worldwide rights to etigilimab, said it plans to initiate talks with other potential partners for the program.
London-listed shares of Mereo were recently down 8.1%.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 13, 2019 08:41 ET (12:41 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Celgene Chart |
1 Month Celgene Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
